BPD - Bronchopulmonary DysplasiaNCT03613987
Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants
A study testing NAVA technology to synchronize NIPPV in people with BPD - Bronchopulmonary Dysplasia, run by New York Medical College at 1 site in United States.
Trial summary
Infants delivered weighing less than 1 kg at birth (ELBW) are at high risk for the development of bronchopulmonary dysplasia (BPD) and Ventilator-Induced Lung Injury (VILI), in part because of the need for mechanical ventilation utilizing an endotracheal tube (MVET). Read more about this study
- Who is it for?
- Ages 24 to 30 weeks
- Conditions the study is for
- BPD - Bronchopulmonary Dysplasia
- What is being tested?
- NAVA technology to synchronize NIPPV
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Apr 2018to 26 Jul 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 24 to 30 weeks
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Babies born less than 1kg.
- Babies born at 24-30 weeks gestation.
- Babies who qualify for surfactant administration within 90mins of birth:
- FiO2 > 0.4,
- nCPAP > 6, with
- Increased work of breathing as noted by grunting; and/or inter-, sub-, or supra-sternal retractions.
Who cannot join
- Babies with Grade 3-4 IVH (may not be known prior to randomization).
- Babies with congenital anomalies including neuromuscular disorder.
- Babies who do not require intubation until 7 days of life.
Trial locations and contacts
1 site in 1 country.
United States1 site
Westchester Medical Center
Valhalla, New York, 10595
About this study
Official title: Randomized Control Trial: Synchronized Non-Invasive Positive Pressure Ventilation (sNIPPV) With Neurally-Assisted Ventilatory Assist (NAVA) Versus NIPPV in Extremely Low Birth Weight Infants
Infants delivered weighing less than 1 kg at birth (ELBW) are at high risk for the development of bronchopulmonary dysplasia (BPD) and Ventilator-Induced Lung Injury (VILI), in part because of the need for mechanical ventilation utilizing an endotracheal tube (MVET). In spite of strategies to minimize the need for MVET, the incidence of BPD in ELBW infants continues to be 20-80%. The hypothesis is that synchronized NIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV.
Read the detailed description
Hypothesis:
The hypothesis is that sNIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV.
Specific Aims:
The specific aims are to determine whether:
- sNIPPV results in a decreased need for MVET at 7days of life and 28 days of life in ELBW infants compared to NIPPV.
- sNIPPV reduces BPD in ELBW infants compared to NIPPV. Research design and methods: ELBW infants will be enrolled in this study at the RNICU at MFCH of WMC following informed written parental consent.
Randomization:
ELBW infants will be randomized to either sNIPPV group or NIPPV group using a computer-generated scheme.
Extubation criteria:
- Infant is receiving caffeine.
- Infants can be extubated at any point, but must be extubated following a 12-hour period of clinical stability when the ventilator settings have met all the following criteria:
- mean airway pressure (MAP) < 8cmH20,
- FiO2 < 0.4,
- pH > 7.2, and
- pCO2 < 70.
Intubation criteria:
Infants must be intubated if any of the following criteria occur:
- One apneic event requiring positive pressure ventilation (PPV).
- More than 6 apneic events requiring stimulation within a 6-hour period.
- A deterioration in respiratory status as noted by any of the following criteria:
- pH < 7.2,
- pCO2 > 70,
- FiO2 > 0.6,
- Or, if in the opinion of the attending neonatologist, the baby is failing either non-invasive strategy.
Data Collection:
Demographic and outcome data will be collected from source data, and then the patient will be given a unique identifier, without reference to MRN or birthdate.
Tracheal aspirates will be collected per routine nursing care to look for inflammatory cytokine markers (IL8, IL6 and TNF alpha). This may help to determine if certain infants remained intubated due to a pro-inflammatory mechanism (if their TA cytokines were elevated early compared to those who may have been more successfully extubated because of low levels of cytokines).
During hospital stay, DNA and RNA samples will be extracted from buccal swabs, as certain babies are more susceptible to BPD based on their genetic foundations.
Charts will be reviewed to determine the duration of oxygen therapy as well as the duration of MVET.
MVET will be assessed at 7 days of life and 28 days of life as primary outcome. BPD, as defined as oxygen requirement at 36 weeks PMA, is a secondary outcome. Initial statistical analysis will be performed using chi square for categorical data; and t-test or Mann Whitney for continuous data that is normally or non-normally distributed (respectively), with statistical significance when P < 0.05.
Power analysis:
Based on the investigators' NICU data that NIPPV has MVET rate at 7 days of life of 84% for ELBWs, it was hypothesized that sNIPPV will decrease the need for MVET at 7 days of life by 40%. For a power of 80%, and an alpha value of 0.05, the sample size is 27 infants in each group. Anticipating a 10% dropout rate, this gives 30 as the sample size for each group.
Anticipated timeline:
With 80-100 ELBW infants admitted each year, enrollment is anticipated to be completed in 1 year.
The clinical implications of this study will determine if synchronized NIPPV in ELBW infants will reduce the need for mechanical ventilation and ultimately BPD.
There are no procedures, situations, or materials that will be hazardous to personnel. There are no courses planned which support the research training experience. This research will not include the use of experimental drugs or treatments.
- Conditions
- BPD - Bronchopulmonary Dysplasia
- Being tested
- NAVA technology to synchronize NIPPV
- Medical subject headings
- Bronchopulmonary Dysplasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NAVA technology to synchronize NIPPVDevice
Neurally adjust ventilator assist is used to synchronize the NIPPV
| Study group | Role | What they receive |
|---|---|---|
| NIPPV | No intervention | non synchronized non invasive positive pressure ventilation |
| NAVA-NIPPV | Experimental | synchronized non invasive positive pressure ventilation with NAVA Receives: Device: NAVA technology to synchronize NIPPV |
What is being measured
The primary outcome is the main question the study is designed to answer.
The need for Mechanical Ventilation via ET tube ( MVET) at 7 days of life
Mechanical ventilation via Endotracheal tube
Measured: 7 days of life
The need for Mechanical Ventilation via ET tube ( MVET) at 28 days of life
Mechanical Ventilation via Endotracheal tube
Measured: 28 days of life
Secondary outcomes (1)
Incidence of BPD or need for supplemental O2 at 36 weeks corrected age
Bronchopulmonary Dysplasia
Measured: 36 weeks corrected gestational age
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2018
- Study start26 Apr 2018
- Primary completion26 Jul 2022
- Study completion26 Jul 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for BPD - Bronchopulmonary DysplasiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- New York Medical College
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lance Parton, MD, Principal investigator, Westchester Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03613987
- Sponsor's protocol ID
- L12,175
- Status last verified
- Mar 2023
- First submitted
- 30 Jul 2018
- Last updated
- 27 Mar 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Publications
Louie K, Amatya S, Alpan G, Parton LA. Non-Invasive Ventilation with Neurally Adjusted Ventilatory Assist (NAVA) Improves Extubation Outcomes in Extremely Low-Birth-Weight Infants. Children (Basel). 2024 Sep 28;11(10):1184. doi: 10.3390/children11101184.
PubMed 39457149
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Control Trial: Synchronized Non-Invasive Positive Pressure Ventilation (sNIPPV) With Neurally-Assisted Ventilatory Assist (NAVA) Versus NIPPV in Extremely Low Birth Weight Infants
- ClinicalTrials.gov ID
- NCT03613987
- Acronym / sponsor ID
- L12,175
- Conditions
- BPD - Bronchopulmonary Dysplasia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- New York Medical CollegeUniversity, hospital or other
- Study start
- 26 Apr 2018 (actual)
- Primary completion
- 26 Jul 2022 (actual)
- Study completion
- 26 Jul 2022 (actual)
- First posted
- 3 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Infants delivered weighing less than 1 kg at birth (ELBW) are at high risk for the development of bronchopulmonary dysplasia (BPD) and Ventilator-Induced Lung Injury (VILI), in part because of the need for mechanical ventilation utilizing an endotracheal tube (MVET). In spite of strategies to minimize the need for MVET, the incidence of BPD in ELBW infants continues to be 20-80%. The hypothesis is that synchronized NIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV.
Detailed description
Hypothesis:
The hypothesis is that sNIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV.
Specific Aims:
The specific aims are to determine whether:
- sNIPPV results in a decreased need for MVET at 7days of life and 28 days of life in ELBW infants compared to NIPPV.
- sNIPPV reduces BPD in ELBW infants compared to NIPPV. Research design and methods: ELBW infants will be enrolled in this study at the RNICU at MFCH of WMC following informed written parental consent.
Randomization:
ELBW infants will be randomized to either sNIPPV group or NIPPV group using a computer-generated scheme.
Extubation criteria:
- Infant is receiving caffeine.
- Infants can be extubated at any point, but must be extubated following a 12-hour period of clinical stability when the ventilator settings have met all the following criteria:
- mean airway pressure (MAP) < 8cmH20,
- FiO2 < 0.4,
- pH > 7.2, and
- pCO2 < 70.
Intubation criteria:
Infants must be intubated if any of the following criteria occur:
- One apneic event requiring positive pressure ventilation (PPV).
- More than 6 apneic events requiring stimulation within a 6-hour period.
- A deterioration in respiratory status as noted by any of the following criteria:
- pH < 7.2,
- pCO2 > 70,
- FiO2 > 0.6,
- Or, if in the opinion of the attending neonatologist, the baby is failing either non-invasive strategy.
Data Collection:
Demographic and outcome data will be collected from source data, and then the patient will be given a unique identifier, without reference to MRN or birthdate.
Tracheal aspirates will be collected per routine nursing care to look for inflammatory cytokine markers (IL8, IL6 and TNF alpha). This may help to determine if certain infants remained intubated due to a pro-inflammatory mechanism (if their TA cytokines were elevated early compared to those who may have been more successfully extubated because of low levels of cytokines).
During hospital stay, DNA and RNA samples will be extracted from buccal swabs, as certain babies are more susceptible to BPD based on their genetic foundations.
Charts will be reviewed to determine the duration of oxygen therapy as well as the duration of MVET.
MVET will be assessed at 7 days of life and 28 days of life as primary outcome. BPD, as defined as oxygen requirement at 36 weeks PMA, is a secondary outcome. Initial statistical analysis will be performed using chi square for categorical data; and t-test or Mann Whitney for continuous data that is normally or non-normally distributed (respectively), with statistical significance when P < 0.05.
Power analysis:
Based on the investigators' NICU data that NIPPV has MVET rate at 7 days of life of 84% for ELBWs, it was hypothesized that sNIPPV will decrease the need for MVET at 7 days of life by 40%. For a power of 80%, and an alpha value of 0.05, the sample size is 27 infants in each group. Anticipating a 10% dropout rate, this gives 30 as the sample size for each group.
Anticipated timeline:
With 80-100 ELBW infants admitted each year, enrollment is anticipated to be completed in 1 year.
The clinical implications of this study will determine if synchronized NIPPV in ELBW infants will reduce the need for mechanical ventilation and ultimately BPD.
There are no procedures, situations, or materials that will be hazardous to personnel. There are no courses planned which support the research training experience. This research will not include the use of experimental drugs or treatments.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| NIPPV | No intervention | –non synchronized non invasive positive pressure ventilation |
| NAVA-NIPPV | Experimental | Device: NAVA technology to synchronize NIPPVsynchronized non invasive positive pressure ventilation with NAVA |
Who may qualify
- Ages
- 24 to 30 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Babies born less than 1kg.
- Babies born at 24-30 weeks gestation.
- Babies who qualify for surfactant administration within 90mins of birth:
Key exclusion criteria (3 listed)
- Babies with Grade 3-4 IVH (may not be known prior to randomization).
- Babies with congenital anomalies including neuromuscular disorder.
- Babies who do not require intubation until 7 days of life.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NAVA technology to synchronize NIPPVNeurally adjust ventilator assist is used to synchronize the NIPPV | Device | NAVA-NIPPV |
Primary outcome
The need for Mechanical Ventilation via ET tube ( MVET) at 7 days of life
Time frame: 7 days of life
Mechanical ventilation via Endotracheal tube
The need for Mechanical Ventilation via ET tube ( MVET) at 28 days of life
Time frame: 28 days of life
Mechanical Ventilation via Endotracheal tube
1 secondary outcome
Incidence of BPD or need for supplemental O2 at 36 weeks corrected age
Time frame: 36 weeks corrected gestational age
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2023.
- Derived from this study: PubMed 39457149Louie K, Amatya S, Alpan G, Parton LA. Non-Invasive Ventilation with Neurally Adjusted Ventilatory Assist (NAVA) Improves Extubation Outcomes in Extremely Low-Birth-Weight Infants. Children (Basel). 2024 Sep 28;11(10):1184. doi: 10.3390/children11101184.
Related trials for BPD - Bronchopulmonary Dysplasia
RecruitingPhase 4
Impact of Higher Zinc Supplementation on Neonatal Weight Velocity
Extreme Prematurity,Extremely Low Birthweight, BPD - Bronchopulmonary Dysplasia
RecruitingObservational study
The Correlation Between Red Cell Transfusion and Complications of Prematurity
Retinopathy of Prematurity (ROP), Bronchopulmonary Dysplasia (BPD)
Not yet recruiting
Parent Perceptions of OptiPAP Junior
Bronchopulmonary Dysplasia (BPD), Preterm Birth Complication
RecruitingObservational study
Chloride Imbalance in Preterm Infants
Bronchopulmonary Dysplasia (BPD), Mortality Prediction
RecruitingPhase 1/2
PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
Bronchopulmonary Dysplasia (BPD), Premature Births
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lance Parton, MD principal investigator
Westchester Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NAVA technology to synchronize NIPPV in people with BPD - Bronchopulmonary Dysplasia, run by New York Medical College at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The need for Mechanical Ventilation via ET tube ( MVET) at 7 days of life (time frame: 7 days of life). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03613987, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2023; AzTrials last refreshed its copy on 29 Oct 2026.